Updated Jul 16, 2026
Danahy Kevin Patrick is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $3.39M.
Kevin Patrick Danahy is the Chief Commercial Officer at Pulse Biosciences, Inc., a company specializing in bioelectric medicine and Nano-Pulse Stimulation technology. He has been involved in the company's operations as indicated by SEC filings, but there is limited public information available about his career.
| Role | Chief Commercial Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-24 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 5.0K | $23.64 | $118K |
| 2026-02-24 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 5.0K | $1.53 | $8K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $23.63 | $473K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $23.53 | $471K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $23.37 | $467K |
| 2026-02-18 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $25.20 | $504K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $23.52 | $470K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale [10b5-1] | 20.0K | $21.45 | $429K |
| 2026-02-12 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise [10b5-1] | 20.0K | $1.53 | $31K |
| 2025-10-02 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale | 4.6K | $18.53 | $85K |
| 2025-10-02 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise | 4.6K | $1.53 | $7K |
| 2025-09-18 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale | 400 | $18.48 | $7K |
| 2025-09-18 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise | 400 | $1.53 | $612 |
| 2025-09-18 | PLSE | PULSE BIOSCIENCES, INC. | S — Open-market sale | 20.0K | $18.49 | $370K |
| 2025-09-18 | PLSE | PULSE BIOSCIENCES, INC. | M — Option exercise | 20.0K | $1.53 | $31K |
Kevin Patrick Danahy is the Chief Commercial Officer at Pulse Biosciences, Inc., a company specializing in bioelectric medicine and Nano-Pulse Stimulation technology. He has been involved in the company's operations as indicated by SEC filings, but there is limited public information available about his career.…
Recorded transactions: 0 open-market purchases () and 10 open-market sales ($3.39M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Danahy Kevin Patrick profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.